Management of patients with hepatitis B who require immunosuppressive therapy

@article{Hwang2014ManagementOP,
  title={Management of patients with hepatitis B who require immunosuppressive therapy},
  author={Jessica P Hwang and Anna S.-F. Lok},
  journal={Nature Reviews Gastroenterology &Hepatology},
  year={2014},
  volume={11},
  pages={209-219}
}
Patients with chronic HBV infection are at risk of reactivation of HBV should they require immunosuppressive therapies for a variety of clinical settings, including chemotherapy for patients with cancer, immunosuppression for solid organ and stem cell transplant recipients, and use of anti-CD20 antibodies, TNF inhibitors, or corticosteroids in patients with oncological, gastrointestinal, rheumatological or dermatological conditions. The key to preventing HBV reactivation is the identification… CONTINUE READING
45 Citations
115 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 45 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 115 references

Boxed Warning and new recommendations to decrease risk of hepatitis B reactivation with the immunesuppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab)

  • US Department of Health, Human Services. FDA Drug Safety Communication
  • US Food and Drug Administration [online], http…
  • 2013

Randomized controlled trial of entecavir prophylaxis for rituximabassociated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B

  • C. Hsu
  • Clin . Oncol .
  • 2013

Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis

  • Huang, H Y.
  • B. J. Clin. Oncol
  • 2013

Similar Papers

Loading similar papers…